Protein detail
CD19
B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19)
Entry name CD19 | UniProt ID | EVMP score 0.38 |
Frequency 7 | Transmembrane count 1 | Protein classification CD markersDisease related genesFDA approved drug targetsHuman disease related genesPredicted membrane proteins |
EVMP score: annotation confidence score.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40
Basic Information
Protein Names
B-lymphocyte antigen CD19 (B-lymphocyte surface antigen B4) (Differentiation antigen CD19) (T-cell surface antigen Leu-12) (CD antigen CD19)
Protein Class
CD markersDisease related genesFDA approved drug targetsHuman disease related genesPredicted membrane proteins
Protein Function
- Human disease related genes:Immune system diseases:Primary immunodeficiency
- Disease related genes
- CD markers
- FDA approved drug targets:Biotech drugs
Transmembrane
292..313; Helical
Transmembrane Count
1
Ensembl
Entrez Gene Symbol
Gene Description
CD19 molecule
Chromosome
16
Position
28931965-28939342
Frequency
7
EVMP Score
0.38
Fluorescence & Localization
Cell SpecificVascular endothelial cells
Function & Pathway
Protein Function
- Human disease related genes:Immune system diseases:Primary immunodeficiency
- Disease related genes
- CD markers
- FDA approved drug targets:Biotech drugs
Cellular Component
Biological Process
KEGG
Reactome
- R-hsa-1280218 adaptive immune system
- R-hsa-983695 antigen activates b cell receptor bcr leading to generation of second messengers
- R-hsa-166658 complement cascade
- R-hsa-2219530 constitutive signaling by aberrant pi3k in cancer
- R-hsa-5663202 diseases of signal transduction by growth factor receptors and second messengers
- R-hsa-198933 immunoregulatory interactions between a lymphoid and a non lymphoid cell
- R-hsa-168249 innate immune system
- R-hsa-9006925 intracellular signaling by second messengers
- R-hsa-199418 negative regulation of the pi3k akt network
- R-hsa-2219528 pi3k akt signaling in cancer
- R-hsa-983705 signaling by the b cell receptor bcr
Canonical Pathways
M275 Pid alpha synuclein pathway
Mediation Categories
Clinical-translation mediationFusion and delivery mediationImmune mediationMetabolism mediationReceptor-signaling mediation
Relations & Evidence
Enzyme-Mediated Modification
23 records.
| Substrate Gene Symbol | Enzyme Gene Symbol | Enzyme UniProt ID | Residue Type | Residue Offset | Modification | Database | References |
|---|---|---|---|---|---|---|---|
| CD19 | LYN | P07948 | Y | 531 | phosphorylation | BEL-Large-Corpus_ProtMapperPhosphoNetworksSIGNORProtMapperHPRDKEAphosphoELMSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | KEA:10933394ProtMapper:15212693KEA:9190913ProtMapper:10933394HPRD:10933394SIGNOR:10933394HPRD:16497976KEA:10201980phosphoELM:10933394 |
| CD19 | LYN | P07948 | Y | 500 | phosphorylation | BEL-Large-Corpus_ProtMapperPhosphoNetworksSIGNORProtMapperHPRDKEAphosphoELMSIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | KEA:10933394ProtMapper:15212693ProtMapper:10933394KEA:9190913HPRD:10933394SIGNOR:10933394KEA:10201980phosphoELM:10933394 |
| CD19 | LYN | P07948 | Y | 409 | phosphorylation | PhosphoNetworksphosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPKEA | KEA:10933394KEA:10706702 |
| CD19 | LYN | P07948 | Y | 532 | phosphorylation | MIMPHPRD_MIMPphosphoELM_MIMPPhosphoSite_MIMP | |
| CD19 | SRC | P12931 | Y | 500 | phosphorylation | Li2012 | |
| CD19 | SRC | P12931 | Y | 531 | phosphorylation | Li2012 | |
| CD19 | ABL1 | P00519 | Y | 508 | phosphorylation | SIGNORProtMapperHPRDKEASIGNOR_ProtMapperPhosphoSitePhosphoSite_ProtMapper | SIGNOR:11120811ProtMapper:11120811HPRD:11120811KEA:11120811 |
| CD19 | ABL1 | P00519 | Y | 509 | phosphorylation | MIMPHPRD_MIMPPhosphoSite_MIMP | |
| CD19 | MAPK1 | P28482 | Y | 348 | phosphorylation | phosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPHPRDKEA | KEA:10706702HPRD:16497976HPRD:10706702 |
| CD19 | MAPK1 | P28482 | Y | 378 | phosphorylation | phosphoELM_MIMPPhosphoSite_MIMPMIMPHPRD_MIMPKEA | KEA:10706702 |
Page 1 of 3Next
Ligand-Receptor Signaling
41 records.
| Category | Parent | Database | Transmitter | Receiver | Secreted | Plasma Membrane (Transmembrane) | Plasma Membrane (Peripheral) |
|---|---|---|---|---|---|---|---|
| receptor | receptor | GO_Intercell | No | Yes | No | Yes | No |
| receptor | receptor | CellTalkDB | No | Yes | No | Yes | No |
| receptor | receptor | Ramilowski2015 | No | Yes | No | Yes | No |
| receptor | receptor | LRdb | No | Yes | No | Yes | No |
| receptor | receptor | Baccin2019 | No | Yes | No | Yes | No |
| receptor | receptor | OmniPath | No | Yes | No | Yes | No |
| extracellular | extracellular | DGIdb | No | No | No | Yes | No |
| extracellular | extracellular | OmniPath | No | No | No | Yes | No |
| intracellular | intracellular | LOCATE | No | No | No | Yes | No |
| intracellular | intracellular | ComPPI | No | No | No | Yes | No |
Page 1 of 5Next
Regulatory Interaction Network
7 records.
Protein Complex Composition
Isolation & Detection Technology
1 record.
| EV Isolation Method | Detection Method | Number of References | References |
|---|---|---|---|
| Protein Organic Solvent Precipitation | Mass spectrometry | 1 | 32384937 |
Sequence, Structure & Domains
Sequences
Length
556
Mass
61,128
Sequence
MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNVSQQMGGFYLCQPGPPSEKAWQPGWTVNVEGSGELFRWNVSDLGGLGCGLKNRSSEGPSSPSGKLMSPKLYVWAKDRPEIWEGEPPCLPPRDSLNQSLSQDLTMAPGSTLWLSCGVPPDSVSRGPLSWTHVHPKGPKSLLSLELKDDRPARDMWVMETGLLLPRATAQDAGKYYCHRGNLTMSFHLEITARPVLWHWLLRTGGWKVSAVTLAYLIFCLCSLVGILHLQRALVLRRKRKRMTDPTRRFFKVTPPPGSGPQNQYGNVLSLPTPTSGLGRAQRWAAGLGGTAPSYGNPSSDVQADGALGSRSPPGVGPEEEEGEGYEEPDSEEDSEFYENDSNLGQDQLSQDGSGYENPEDEPLGPEDEDSFSNAESYENEDEELTQPVARTMDFLSPHGSAWDPSREATSLGSQSYEDMRGILYAAPQLRSIRGQPGPNHEEDADSYENMDNPDGPDPAWGGGGRMGTWSTR
Alternative Products
Event=Alternative splicing; Named isoforms=2; Name=1; IsoId=P15391-1; Sequence=Displayed; Name=2; IsoId=P15391-2; Sequence=VSP_047194
Alternative Sequence
495; L -> LA (in isoform 2)
3D Structural Models
Helix
89..91; 203..205; 253..255
Beta Strand
24..29; 34..36; 50..55; 61..75; 80..84; 93..100; 108..115; 119..125; 155..160; 163..166; 187..190; 196..198; 208..218; 221..230; 239..242; 245..250; 257..262; 267..275
3D Structure
Electron microscopy (3); X-ray crystallography (1)
Domain & Motif Annotations
Compositional Bias
343..355; Polar residues; 401..422; Acidic residues; 423..436; Polar residues; 441..454; Acidic residues
Domain (FT)
20..113; Ig-like C2-type 1; 176..277; Ig-like C2-type 2
Region
329..355; Disordered; 372..497; Disordered; 513..556; Disordered
Clinical Relevance
Disease Involvement
FDA approved drug targets
Related Diseases
Acute myeloid leukaemiaB-cell lymphomaDiabetes mellitusDiffuse large B-cell lymphomaEncephalopathyFollicular lymphomaHodgkin lymphomaImmune system diseaseImmunoproliferative disorderLeukaemiaLupus erythematosusLymphomaMalignant haematopoietic neoplasmMature B-cell leukaemiaMature B-cell lymphomaMultiple myelomaNervous system paraneoplastic/autoimmune disorderNeuromyelitis opticaPancreatic cancerPrecursor B-lymphoblastic neoplasmRheumatoid arthritisSjogren syndromeSystemic sclerosis
Biomarker
Phase 1/2; Phase 2/3; Phase 2; Approved; Phase 0; Phase 1; Phase 3
Drug Targets
FDA approved drug targets
Drugs
AUTOLOGOUS CD19 CAR-EXPRESSING CD4+/CD8+ T-CELLS MB-CART19.1AUTOLOGOUS ANTI-CD19 CAR-EXPRESSING T-LYMPHOCYTES CLIC-1901TISAGENLECLEUCELDUVORTUXIZUMABAUTOLOGOUS ANTI-CD19CAR-4-1BB-CD3ZETA-EGFRT-EXPRESSING T LYMPHOCYTESCOLTUXIMAB RAVTANSINEONCOLYSIN BDENINTUZUMAB MAFODOTINAUTOLOGOUS CD19CAR-CD28-CD137/CD27/CD3ZETA-ICASP9-EXPRESSING T-LYMPHOCYTESLISOCABTAGENE MARALEUCELMDX-1342AXICABTAGENE CILOLEUCELBLINATUMOMABRELMACABTAGENE AUTOLEUCELCD19CAR-CD3ZETA-4-1BB-EXPRESSING ALLOGENEIC T-LYMPHOCYTE CELLSANTI-CD19 CAR T-CELLS XLCART001TAFASITAMABINEBILIZUMAB-CDONDEGLYCOSYLATED RICIN A CHAIN-CONJUGATED ANTI-CD19/ANTI-CD22 IMMUNOTOXINSAUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS C-CAR011LONCASTUXIMAB TESIRINEOBEXELIMABAMG-729BREXUCABTAGENE AUTOLEUCELANTI-CD19 CAR T CELLS PREPARATIONANTI-CD20 CAR T CELLS PREPARATIONAUTO3ALLOGENEIC ANTI-CD19-CAR-CD28-IL-15-EXPRESSING NATURAL KILLER T-CELLSTAPLITUMOMAB PAPTOXAFM-11AUTOLOGOUS ANTI-CD19 CAR T-CELLS IM19JCAR014DENINTUZUMABAZERCABTAGENE ZAPRELEUCELAUTOLOGOUS ANTI-CD19 CAR-T CELLS TBI-1501CD19-TARGETED CAR T2 CELLSVADACABTAGENE LERALEUCELAUTOLOGOUS ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR T-CELLS SJCAR19
Antibody